Abstract

Poly (ADP-ribose) polymerase (PARP) inhibitors have emerged as a significant class of targeted therapies in oncology, particularly in the treatment of cancers with homologous recombination deficiency, such as those with BRCA mutations. This review explores the molecular mechanisms underlying PARP inhibitors, their clinical efficacy, and the challenges associated with their use. By providing a detailed examination of the pharmacodynamics, clinical trials, and potential future directions of PARP inhibitors, this article aims to enhance understanding of their therapeutic potential and limitations in cancer treatment.